Inflammatory responses mounted to eliminate parasites can be lethal if not counterbalanced by regulatory responses protecting the host from collateral tissue damage. Here, we show that the maintained inflammation associated with tissue damage, anemia, and reduced survival of Trypanosoma brucei-infected mice correlates with the absence of the expansion of the regulatory T (T reg ) cell population. Induction of T reg cell expansion via CD28 superagonist antibody treatment in these mice down-regulated interferon-␥ production by T cells and tumor necrosis factor-␣ and reactive oxygen species production by classically activated macrophages, triggered the development of alternatively activated macrophages, delayed the onset of liver injury, diminished the anemia burden, and prolonged the survival of infected animals. Thus, triggering the expansion of the T reg cell population coupled with the induction of alternatively activated macrophages can restore the balance between pro-and anti-inflammatory signals and thereby limit the pathogenicity of African trypanosomiasis.
Uncontrolled inflammation is a major cause of pathogenicity during chronic parasite infections [1] [2] [3] [4] . Novel therapies should therefore aim to reestablish the balance between pro-and anti-inflammatory signals during disease to avoid tissue damage and ensure survival of the host. In this context, we intended to identify strategies that could induce counterinflammatory activity and thereby increase the resistance of the host to parasite infection, using African trypanosomiasis as a model.
During natural as well as experimental African trypanosomiasis, a broad range in the severity of disease patterns is associated with different host-trypanosome combinations (reviewed in [5, 6] ). Because of their accessibility, mouse models are currently used to understand factors governing the ability of the host to protect itself from immune-mediated damage during African trypanosomiasis. In C57BL/6 mice, Trypanosoma congolense causes a subpathogenic infection with milder disease symptoms than those caused by Trypanosoma brucei (pathogenic), as reflected by reduced tissue damage, moderate (lower) anemia, and prolonged survival of the host. C57BL/6 mice infected with T. congolense and those infected with T. brucei parasites both require an interferon (IFN)-␥-driven type 1 immune response and tumor necrosis factor (TNF)-␣-producing classically activated macrophages (M1) during the early stage of infection to control the first and most aggressive peak of parasitemia [7] [8] [9] [10] [11] [12] . However, once this first peak of parasitemia is controlled, C57BL/6 mice infected with T. congolense, but not those infected with T. brucei, move to a type 2 immune response, as evidenced by high interleukin (IL)-10 secretion and the development of alternatively activated macrophages (M2) [10] . The increased pathogenicity in T. brucei-infected mice correlates with the inability of the host to suppress the type 1 immune response [8, 13, 14] . Moreover, IL-10 is crucial to limit pathogenicity during T. congolense and T. brucei infection, because mice deficient in IL-10 signaling suffer severe tissue damage due to the uncontrolled type 1 inflammation and have shortened survival [14, 15] . On the other hand, we have recently reported that IL-10 -producing Foxp3 ϩ regulatory T (T reg ) cells contribute to the suppression of IFN-␥ and TNF-␣ production during T. congolense infection [15] . This T reg cellmediated suppression of the type 1 immune response proved to be essential to protect the tissues from pathogenic damage, maintaining the parasite-clearing capacity of the liver and allowing the development of a chronic infection lasting for 148 Ϯ 21 days. However, it is currently unknown whether T reg cells are elicited and influence the severity of disease in T. brucei-infected hosts.
Here, we show that the population of T reg cells does not expand in T. brucei-infected C57BL/6 mice undergoing a pathogenic infection, in contrast to T. congolense-infected C57BL/6 mice that develop a subpathogenic infection [15] . Subsequently, we aimed to induce a more resistant phenotype in T. bruceiinfected mice by inducing T reg cell expansion via CD28 superagonist antibody treatment. This treatment efficiently suppressed the type 1 inflammation and induced M2 activation, leading to diminished anemia, delayed liver damage, maintenance of the parasite-clearance capacity, and prolonged survival of T. brucei-infected mice.
METHODS
Parasites, mice, and infections. T. congolense variant antigen type 13 (Tc13) organisms [16] were provided by Dr. H. Tabel (University of Saskatchewan, Canada). T. brucei AnTat 1.1E organisms [17] were a gift from N. Van Meirvenne (Institute for Tropical Medicine, Belgium). Parasites that had been stored at Ϫ80°C were used to infect cyclophosphamide-treated F1 (C57BL/6 ϫ BALB/c) mice (bred in-house) by intraperitoneal inoculation. On day 4 after infection, mice were bled, and parasites were purified by diethylaminoethyl cellulose chromatography [18] . Female C57BL/6 mice (Harlan) kept under filter barrier were then infected at 8 -12 weeks of age with 2000 purified parasites. Parasitemia and red blood cell counts were monitored by tail blood puncture using a Bürker counting chamber. Experiments were performed in compliance with the relevant laws and institutional guidelines. A CD28 superagonist antibody (D665 [19] ) or control antibody (MOPC-31C as isotype-matched negative control) was injected intravenously (200 g in 200 L of PBS) 1 h before intraperitoneal infection with the parasites.
Isolation of liver immune cells. Liver nonparenchymal cells were isolated as follows. Animals were killed (with CO 2 ), and livers were perfused through the portal vein with 10 mL of 100 U/mL collagenase type 3 (Worthington Biochemical) in Hank's balanced salt solution (HBSS). Then the liver was minced and incubated in 10 mL of 100 U/mL collagenase type 3 (20 min at 37°C). The resulting cell suspension was passed through a 100-m nylon mesh filter and then centrifuged (300 g for 10 min at 4°C). After erythrocyte lysis, the pellet was resuspended in 10 mL of HBSS supplemented with 2 mmol/L EDTA and 10% fetal calf serum (FCS) and overlaid on 10 mL of Lymphoprep solution (Lucron Bioproducts). After centrifugation (430 g for 30 min at 17°C), the layer of low-density cells at the interface containing nonparenchymal cells was harvested.
Quantification of cytokines. To evaluate IFN-␥ and IL-10 production by T cells, liver cells were resuspended at 2 ϫ 10 6 /mL in RPMI 1640 (Gibco) supplemented with 10% heat-inactivated FCS, 100 U/mL penicillin, 100 g/mL streptomycin, 0.1 mmol/L nonessential amino acids, 2 mmol/L L-glutamine, and 5 ϫ 10 -5 mol/L 2-mercaptoethanol (Invitrogen Life Technologies) and incubated in the presence of 1 g/mL anti-CD3 antibody (clone 145-2C11). Spontaneous TNF-␣ production by macrophages was also assessed. Cytokines were quantified in culture supernatants collected after 3 days by use of specific sandwich ELISAs for IFN-␥, IL-10 (Pharmingen), or TNF-␣ (R&D Systems), in accordance with manufacturers' protocols.
Flow cytometry analysis. For surface markers, liver immune cells were stained for 30 min at 4°C using conventional protocols. Cells were incubated with anti-Fc␥R antibody (clone 2.4G2) before the addition (at 1 g/1 ϫ 10 6 cells) of fluorescein isothiocyanate (FITC)-conjugated anti-CD8a (clone Ly-2), phycoerythrin (PE)-cyanine 5 or allophycocyanin-conjugated anti-CD4 (clone L3T4) antibodies, FITC-conjugated major histocompatibility complex class I (MHC-I; clone AF6 -88.5), FITC-conjugated MHC-II (clone M5/114.15.2), FITC-conjugated or PE-cyanine 7-conjugated CD11b (clone M1/70), PEconjugated F4 -80 (clone MCA497), FITC-conjugated CD80 (16 -10A1), or FITC-conjugated CD86 (Gl-1) antibodies. Intracellular staining was performed in accordance with manufacturers' protocols, using PE-conjugated anti-IL-10 (JES5-16E3), anti-IFN-␥ (clone XMG1.2), and FITC-or PE-conjugated antiFoxp3 (FJK-16s) antibodies. All antibodies were purchased from BD Biosciences, with the exception of anti-Foxp3 (eBioscience). For intracellular IFN-␥ and IL-10 staining, cells were cultured for 2 h on anti-CD3-coated plates (clone 145-2C11) or with phorbol myristateacetate/ionomycin, respectively, before the addition of brefeldin A (BD Biosciences). Four hours later, cells were fixed, permeabilized (fix/perm kit; eBioscience), and analyzed by use of a FACSVantage SE or FACSCanto II flow cytometer (BD Biosciences), using CellQuest (version 3; BD Biosciences) or FlowJo (version 7.2.1; Tree Star) software, respectively.
Reactive oxygen species (ROS). ROS production was measured using 2',7'-dichlorodihydrofluorescein diacetate (H 2 DCFDA) as a probe. Briefly, cells (1 ϫ 10 6 ) were incubated in serum-free Dulbecco's modified Eagle medium containing 2 mol/L H 2 DCFDA (30 min at 37°C), washed twice with excess RPMI 1640, and analyzed by flow cytometry.
Gene expression analysis. CD11b ϩ cells were isolated from liver immune cells by positive CD11b selection on magnetic separation columns according to the manufacturer's protocol (Miltenyi Biotec), with purity ranging from 85% to 95%. Gene expression in the isolated populations was analyzed by quantitative real-time polymerase chain reaction (PCR), using conditions described elsewhere [20] . Results of the PCR analyses were normalized against the housekeeping gene S12. Primers used were as follows: for S12, Microscopy and levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Liver samples were fixed in Bouin solution (Sigma). Histologic sections embedded in paraffin were stained with hematoxylin-eosin-saffron. ALT and AST levels were measured in serum samples, using commercially available kits (Boehringer Mannheim).
Statistical analysis. All comparisons were tested for statistical significance using the unpaired t test with Welch's correction in GraphPad Prism software (version 4.0; GraphPad).
RESULTS

No expansion of the T reg cell population in mice that develop a pathogenic T. brucei infection.
In the present study, we investigated whether T reg cells develop and affect the course of infection in T. brucei-infected C57BL/6 mice. In these animals, the first peak of parasitemia was controlled efficiently, but a phenotype developed that was relatively pathogenic compared with that in T. congolense-infected mice; this was shown by severe anemia and liver damage, resulting in a sudden loss of ability to control parasitemia on approximately day 30 after infection and in death at a mean Ϯ SE of 31 Ϯ 3 days after infection (figure 1). Because the liver has been suggested to be the major site for trypanosome clearance [11, 12] , we evaluated the immune modulations in this organ during T. brucei infection. As shown in figure 1D -1F, infected mice maintained IFN-␥ and TNF-␣ production and produced low levels of IL-10 during the entire course of infection. The number of naturally occurring CD4 ϩ
Foxp3
ϩ T reg cells in the liver augmented as a function of time after infection (figure 1G). However, this merely reflected the increase in the total number of CD4 ϩ T cells (figure 1H) due to infection-induced hepatomegaly ( figure 1I) . Indeed, the gradual increase in the number of CD4 ϩ Foxp3 ϩ T reg cells was not accompanied by an increase in the percentage of this population within the CD4 ϩ T cell population (figure 1J), indicating that the population of naturally occurring T reg cells did not preferentially expand in T. brucei-infected mice. Hence, the absence of T reg cell expansion correlates with high pathogenicity in T. brucei-infected mice, as reflected by increased liver injury, high levels of anemia, and decreased survival compared with that in T. congolense-infected mice [15] . We hypothesized that the pathogenicity of T. brucei infection results from the impaired downregulation of type 1 inflammation, caused by the absence of T reg cell expansion.
Pathogenicity of T. brucei infection limited by the in vivo expansion of the T reg cell population.
To evaluate whether the expansion of the T reg cell population could limit the severity of T. brucei infection, we used the mouse anti-mouse CD28 superagonist antibody D665 [19] , which has been documented to induce the expansion and activation of naturally occurring T reg cells [21, 22] . Mice were treated with the CD28 superagonist antibody or with a control antibody 1 h before infection with T. brucei. In noninfected and infected mice, treatment with the CD28 superagonist antibody induced a similar and transient expansion of the Foxp3 ϩ T reg cell population within the CD4 ϩ T cell population in the liver for ϳ2 weeks ( figure 2A ). This resulted in increased numbers of CD4 ϩ Foxp3 ϩ T reg cells in the livers of noninfected and infected mice during the first 2 weeks after anti-CD28 superagonist treatment ( figure 2B ). This treatment also induced elevated IL-10 production from these cells but not from CD4 ϩ Foxp3 Ϫ cells in both experimental groups (figure 2C). The transient induction of T reg cells in infected anti-CD28 superagonist-treated mice was paralleled by a significant decrease in IFN-␥ and TNF-␣ secretion by immune cells isolated from the liver ( figure 3A and 3B ). This did not influence the parasite-clearance capacity of the host, because the height of the first peak of parasitemia was comparable in mice treated with the CD28 superagonist antibody and those treated with control antibody (data not shown). On the other hand, this temporary down-regulation of the type 1 immune response coupled with the increased IL-10 secretion in infected anti-CD28 superagonist-treated mice ( figure 3C ) was sufficient to delay the development of liver damage, as evidenced by ALT ( figure 4A ) and AST (data not shown) levels, and to prolong the survival of T. bruceiinfected mice (mean Ϯ SE, 44 Ϯ 6 days vs. 31 Ϯ 3 days) ( figure 4B ).
Microscopic examination of the liver on day 28 after infection revealed ischemic infarcts in T. brucei-infected mice treated with control antibody (3/4 mice), but none were observed in those treated with CD28 superagonist antibody (4 mice) ( figure 4C and 4D). Lobular and portal mononuclear infiltrates, composed mainly of lymphocytes in portal tracts and lymphocytes mixed with monocytes in sinusoidal spaces, varied from mild to moderate in the 2 experimental groups. However, the amounts of inflammatory cells did not differ significantly between T. bruceiinfected mice treated with CD28 superagonist antibody and those treated with control antibody, indicating that the activation state, not the number of inflammatory cells, determines the severity of tissue damage. Anti-CD28 superagonist treatment also diminished the severity of the anemia burden in T. bruceiinfected mice (figure 5). As for liver damage, however, the beneficial effect of anti-CD28 superagonist treatment was transient, and no significant difference in red blood cell count was observed once the percentage of T reg cells fell back to control levels (i.e., from day 14 after infection) (figure 2). Thus, the transient expansion of the T reg cell population induced by anti-CD28 superagonist treatment results in increased production of IL-10 and limits the type 1 immune response, thereby temporarily decreasing the pathogenicity of T. brucei infection and prolonging the survival of the host. 
Inducement of a switch from M1 to M2 activation during T. brucei infection caused by in vivo expansion of the T reg cell population. It was recently reported that T reg cells can block the classical inflammatory responses of human macrophages (M1) and induce an alternative (M2) activation status in vitro.
Not only did macrophages cocultured with T reg cells show lower TNF-␣ production and lower expression of CD86 and HLA-DR after lipopolysaccharide stimulation, but they also up-regulated the expression of markers typical for M2 macrophages, including mannose receptor 1 (Mrc1; CD206) [23] .
To evaluate the effect that in vivo expansion of the T reg cell population has on macrophage activation, we analyzed MHC-I, MHC-II, CD80, and CD86 levels as well as ROS production by CD11b ϩ F4/80 ϩ cells on day 7 after T. brucei infection in anti-CD28 superagonist-treated and control antibody-treated mice.
As shown in figure 6 , in control antibody-treated infected mice, the expression of MHC-I, MHC-II, CD80, and CD86 and the accumulation of ROS in macrophages increased compared with that in noninfected animals, confirming their M1 activation status [24] . Expansion of the T reg cell population in T. brucei-infected mice treated with CD28 superagonist antibody inhibited the increase in MHC-I, MHC-II, CD80, and CD86 expression. Moreover, T reg cell expansion suppressed ROS accumulation in macrophages. Together with the diminished TNF-␣ production (figure 3), this indicates that the anti-CD28 superagonist-induced expansion of the T reg cell population was able to inhibit the M1 activation of macrophages during T. brucei infection. A number of genes have been identified that are preferentially expressed by M2 macrophages elicited during T. congolense infection as well as in other pathological situations associated with the emergence of M2 macrophages (e.g., helminth infection and cancer progression) [20] . Within this pool of genes, 8 were either IL-10 inducible in vitro in macrophages from noninfected mice (Arg1, Sepp1, Mgl1, Mrc1, and Folr2 [20] ) or IL-10 dependent during T. congolense infection (Sepp1, Ctss, F13a1, and Ngfb [25] ). Indeed, these latter genes were induced in macrophages from T. congolense-infected wild-type mice but not in IL-10 knockout mice. Therefore, we evaluated whether the expansion of the T reg cell population triggered by anti-CD28 superagonist treatment in T. brucei-infected mice induced the expression of IL-10 -dependent, M2-associated genes. Figure 7 shows that, as expected given the M1 activation status of macrophages from T. brucei-infected mice [13] , none of these genes was significantly up-regulated in control antibody-treated infected animals. However, anti-CD28 superagonist treatment significantly induced the expression of Sepp1, Mgl1, Mrc1, Folr2, Ctss, and F13a1 in infected mice. This finding indicates that macrophages from T. brucei-infected mice can efficiently be switched from a classical to an alternative activation state by expanding the population of IL-10 -producing T reg cells and confirms that M2 activation is associated with decreased pathogenicity of African trypanosomiasis [10] . Three experiments were performed, with similar results. *P Ͻ .05, for the comparison between control antibody-treated and anti-CD28 superagonist-treated mice. SA, superagonist.
DISCUSSION
Several pathogens have been reported to induce the expansion of the T reg cell population (reviewed in [26] ), including naturally occurring Foxp3 ϩ T reg cells [27] and induced T reg cells, comprising Tr1 cells [28] and Th3 cells [29, 30] . This expansion can be beneficial for the pathogen, because down-regulation of the inflammatory immune response mounted by the host to eliminate the parasite can ensure parasite persistence and transmission [27, [31] [32] [33] . Such down-regulation of inflammation can also be important in protecting the host from potentially lethal collateral tissue damage associated with the infection [34, 35] . Therefore, in infections associated with sustained inflammation, enhancement of T reg cell activity could suppress the pathogenic inflammatory responses and increase host resistance to the disease.
In rodents, anti-CD28 superagonists preferentially induce the expansion of the population of naturally occurring CD4 ϩ CD25 T reg cells in vivo without additional triggering of the T cell receptor complex [21, 22] . These T reg cells maintain Foxp3 expression, produce high levels of IL-10, and display fully functional suppressive activity, preventing autoimmune disorders in animal models of neuritis, adjuvant arthritis, and experimental autoimmune encephalomyelitis [36, 37] . Although translation of anti-CD28 superagonist therapy into humans recently failed because of an unexpected cytokine-release syndrome [21, 38] , findings in rodents have established the therapeutic potential of transient polyclonal T reg cell activation.
In our present experiments, we used the novel mouse antimouse CD28 superagonist D665. We found that a single injection of the monoclonal D665 antibody before infection with T. brucei induced the expansion of the population of Foxp3 ϩ T reg cells producing high levels of IL-10 and down-regulated the production of IFN-␥ by CD4 ϩ and CD8 ϩ effector T cells (data not shown) as well as the production of TNF-␣ and ROS by M1 macrophages. In addition, the expansion of the naturally occurring T reg cell population inhibited the increase in MHC-I, MHC-II, CD80, and CD86 expression on macrophages, suggesting that macrophages from anti-CD28 superagonist-treated mice could be less potent antigen-presenting cells than macrophages from control antibody-treated mice [39] . Anti-CD28 superagonist treatment not only suppressed the proinflammatory character of M1 macrophages but also triggered the development of M2 macrophages, expressing upregulated levels of IL-10 -inducible genes with potential antiinflammatory and wound-healing properties, including Sepp1, Mgl1, Mrc1, Folr2, Ctss, and F13a1 [40] . This switch in macrophage-activation status was coupled with a delayed onset of liver injury and an attenuated anemia burden, resulting in significantly prolonged survival of T. brucei-infected mice. The experimental expansion of the naturally occurring T reg cell population during pathogenic T. brucei infection appears to induce an immune environment that strongly resembles that found during subpathogenic T. congolense infection. Because anti-CD28 superagonist treatment triggered the development of Foxp3 ϩ T reg cells and M2 macrophages, both cell populations can cooperate to lower the severity of T. brucei infection in treated hosts. The difference in the outcomes of T. brucei and T. congolense infection in C57BL/6 mice can probably not be attributed solely to the absence or presence, respectively, of naturally occurring T reg cells and M2 macrophages. For instance, a role for Foxp3 -Tr1 or Th3 T reg cells cannot be excluded, considering that transforming growth factor-␤ production is up-regulated during African trypanosomiasis [41] [42] [43] [44] [45] . In addition, there could be other fundamental differences between these phylogenetically distinct parasites [46] that affect virulence in mice, including their ability to invade extravascular compartment (T. brucei) or to remain strictly intravascular (T. congolense). In addition, different T. congolense and T. brucei isolates display a range of virulence in C57BL/6 mice. Therefore, the conclusions drawn in our present experiments apply to the specific T. brucei AnTat 1.1 and T. congolense Tc13 models and not necessarily to all experimental or natural T. brucei or T. congolense infections.
The anti-CD28 superagonist treatment in T. brucei-infected mice reduced the type 1 immune response, which is required for efficient parasite control during the early stage of infection [8, 47] . However, this did not impair the capacity of the host to control the parasite. Thus, the type 1 immune response can be dampened to a certain extent without impairing the control of T. brucei growth, and the major factor determining whether the host will develop a pathogenic or subpathogenic infection is its ability to limit the tissue injury associated with type 1 inflammation. In agreement with this notion, we have recently shown that the absence of Foxp3 ϩ T reg cells in T. congolense-infected mice did not lead to an enhanced parasite-clearance capacity, despite the increased type 1 immune response during the early stage of infection, but rather exacerbated the inflammation-induced damage, leading to liver destruction, loss of parasite-clearance capacity during the chronic stage of infection, and diminished survival [15] .
The role played by M2 macrophages that emerges in the chronic stage of African trypanosomiasis during a subpathogenic infection is currently unknown. These cells have been postulated to exert wound healing and anti-inflammatory properties [10, 48, 49] . The activation of M2 macrophages may favor the resistance to African trypanosomiasis by contributing to the repair of tissue damage caused by the disproportionate or prolonged release of inflammatory molecules by M1 macrophages, including TNF-␣ and ROS [8] . In particular, the delayed onset of injury to the liver through activation of M2 macrophages in mice treated with CD28 superagonist antibody may preserve the ability of this organ to control parasitemia for a longer time, thereby prolonging the survival of the host. However, the mechanisms by which M2 macrophages contribute to the antiinflammatory processes elicited during African trypanosome infection remain to be elucidated. In this regard, we have initiated experiments to address the functional implications of M2 macrophage-associated genes in T. congolense infection, starting with the gene product of Sepp1 (which codes for selenoprotein P). Current data show that selenoprotein P favors the resistance to African trypanosomiasis by reducing the pathogenicity of the disease. Through antioxidant properties, selenoprotein P limits the production of ROS, therefore protecting liver tissues and macrophages from damage mediated by type 1 inflammation [25] . In summary, we have shown that experimental expansion of T reg cells can decrease the pathogenicity of an African trypanosome infection by protecting the host against the harmful type 1 inflammatory immune response and associated damage, including anemia and liver injury. Induction of T reg cell activity might be of therapeutic value in various infections in which chronic inflammation causes immunopathology.
